About 960 healthy participants aged between 18 and 85 years will be recruited for the trial. Credit: Arek Socha from Pixabay.

BioNTech and Shanghai Fosun Pharmaceutical (Fosun Pharma) have initiated Phase II clinical trial of their lead mRNA Covid-19 vaccine candidate, BNT162b2, in Taizhou and Lianshui, Jiangsu Province, China.

Jiangsu Provincial Center for Disease Control and Prevention (Public Health Research Institute of Jiangsu Province) will conduct the trial.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial will take place at Taizhou China Medical City Vaccine Engineering Center and Lianshui County CDC, Jiangsu Taizhou People’s Hospital, Lianshui County People’s Hospital and other units.

Approximately 960 healthy participants aged between 18 and 85 years will be recruited through online mode to evaluate the safety and immunogenicity of BNT162b2, as well as to support future Biologic License Application (BLA) in the country.

BioNTech CEO and co-founder Ugur Sahin said: “From the very beginning, our common goal has been to quickly design and develop a safe and effective vaccine for global supply.

“The clinical trial research carried out in China is an important part of the global research and development of BioNTech’s Covid-19 vaccine and marks an important step in bringing this vaccine to the people of China.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Fosun Pharma partnered with BioNTech in March to jointly develop and commercialise vaccine products for Covid-19 based on its mRNA technology platform in Mainland China, Hong Kong and Macau Special Administration Region and the Taiwan Region.

Final analysis data from the Phase III trial of BNT162b2 conducted by Pfizer and BioNTech indicated that it met all primary efficacy endpoints with an efficacy rate of 95% in preventing symptomatic Covid-19 infection.

BNT162b2 is currently under review by regulatory authorities in Europe, the UK and Canada.